Literature DB >> 15837226

Insufficient protection for healthy elderly adults by tetanus and TBE vaccines.

Ursula Hainz1, Brigitte Jenewein, Esther Asch, Karl-P Pfeiffer, Peter Berger, Beatrix Grubeck-Loebenstein.   

Abstract

Little information is available on post-vaccination antibody concentrations and the duration of protection in persons of more than 20 years of age. We, therefore, measured antibodies specific for tetanus (TT) or tick-borne encephalitis (TBE) virus in 734 adults (age 18-93 years, 382 females and 352 males) and evaluated these data in connection with the time point of the last vaccination against tetanus or TBE and age. This analysis revealed that the time of the last vaccination as well as age had highly significant effects on tetanus and TBE titers (p < 0.001). Our results show a strong decline in post-vaccination antibody concentrations with age, which sets in at the age of 40 in the case of tetanus, and is observed right throughout adult life in the case of TBE. Persons over 60 years of age frequently do not have protective antibody concentrations. We conclude that immunological responsiveness to vaccination decreases throughout adult life, and that conventional vaccination strategies designed for children and young adults cannot be uncritically applied in the elderly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837226     DOI: 10.1016/j.vaccine.2005.01.085

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  57 in total

1.  Mechanistic insights into the impairment of memory B cells and antibody production in the elderly.

Authors:  Judith H Aberle; Karin Stiasny; Michael Kundi; Franz X Heinz
Journal:  Age (Dordr)       Date:  2012-01-27

2.  Down syndrome: is it really characterized by precocious immunosenescence?

Authors:  Maaike Aa Kusters; Ruud Hj Verstegen; Esther de Vries
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

3.  TBE--update on vaccination recommendations for children, adolescents, and adults.

Authors:  Tomas Jelinek
Journal:  Wien Med Wochenschr       Date:  2012-06-12

4.  Tick-borne encephalitis and golden agers: position paper of the International Scientific Working Group on Tick-borne encephalitis (ISW-TBE).

Authors:  Zsuzsanna Jelenik; Michael Keller; Benjamin Briggs; Göran Günther; Mats Haglund; Henrieta Hudeckova; Eva Jilkova; Aukse Mickiene; Birger Sandell; Robert Steffen; Franz Strle
Journal:  Wien Med Wochenschr       Date:  2010-05

Review 5.  Impact of aging on dendritic cell functions in humans.

Authors:  Anshu Agrawal; Sudhir Gupta
Journal:  Ageing Res Rev       Date:  2010-07-07       Impact factor: 10.895

Review 6.  Sex and Gender Impact Immune Responses to Vaccines Among the Elderly.

Authors:  Ashley L Fink; Sabra L Klein
Journal:  Physiology (Bethesda)       Date:  2015-11

7.  Failure of antibody response to polysaccharide antigen in treated panhypopituitary adults.

Authors:  A Mukherjee; M Helbert; W D J Ryder; R Borrow; J R E Davis; S M Shalet
Journal:  Clin Exp Immunol       Date:  2009-02-10       Impact factor: 4.330

8.  Improving tetanus prophylaxis in the emergency department: a prospective, double-blind cost-effectiveness study.

Authors:  Muriel Stubbe; Luc J M Mortelmans; Didier Desruelles; Rohnny Swinnen; Marc Vranckx; Edmond Brasseur; Philippe E Lheureux
Journal:  Emerg Med J       Date:  2007-09       Impact factor: 2.740

9.  An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen.

Authors:  Sue Stacy; Amanda Pasquali; Valerie L Sexton; Angelene M Cantwell; Ellen Kraig; Peter H Dube
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.

Authors:  Peter F Wright; Sharon Ankrah; Susan E Henderson; Anna P Durbin; Jim Speicher; Stephen S Whitehead; Brian R Murphy; Alexander G Pletnev
Journal:  Vaccine       Date:  2008-01-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.